

Solid Tumors Malignant Melanoma Cancer Non Hodgkin Lymphoma (NHL) Ovarian Cancer Breast Cancer Thyroid Cancer Head and Neck Cancer

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Trial Status
Active, not recruiting

Trial Runs In
16 Countries

Trial Identifier
NCT02568267
2015-003385-84,GO40782
RXDX-101-02

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT02568267 2015-003385-84,GO40782 RXDX-101-02
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No